Amgen: FDA Approves Update To IMDELLTRA Prescribing Information, Cuts Monitoring Time For Two Doses

Amgen announced that the FDA approved an update to IMDELLTRA's prescribing information that substantially reduces recommended monitoring time for patients' first two doses in an appropriate healthcare setting. The label update could improve treatment convenience and reduce administration burdens, supporting adoption of the therapy.